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http:WHAT THIS PAPER ADDS
Endovascular treatment of patients with critical limb ischemia should preferably be done using balloon an-
gioplasty with optional bailout stenting for below-the-knee arterial lesions. The use of drug-eluting balloons in
these patients, especially diabetic patients, seems promising, but more studies focusing on clinical outcomes are
needed before this strategy can be implemented into standard clinical care. Bare stents, when bailout stenting is
indicated, are recommended over drug-eluting stents, as trials have not shown clinically signiﬁcant differences.Objective: To evaluate 1 to 48 month follow-up outcomes of different endovascular treatment strategies in
below-the-knee (BTK) arterial segments in critical limb ischemia (CLI) patients.
Methods: Medline and Embase were searched (last searched on 5 November 2013) for studies of randomized
controlled trials comparing either balloon angioplasty (PTA) or drug-eluting balloon (DEB) with optional bailout
stenting, or primary stenting using a bare stent (BS) or drug-eluting stent (DES) to one another. Methodological
quality of each trial was assessed using a Cochrane Collaboration’s tool, and quality of evidence was assessed
using the GRADE system. Outcomes assessed were wound healing, quality of life, change in Rutherford
classiﬁcation, amputation, death, target lesion revascularization (TLR), bypass, binary restenosis, late lumen loss,
stenosis grade, and event-free survival with follow-up periods of at least 1 month.
Results: Twelve trials including 1145 patients were identiﬁed, with 90% of patients having CLI. Six BS versus PTA
and two DES versus PTA trials showed low-quality evidence of equal efﬁcacy. One trial, comparing DEB with PTA,
showed moderate-quality evidence of improved wound healing (RR 1.28; 95% CI: 1.05 to 1.56; p ¼ .01),
improvement in Rutherford classiﬁcation (RR 1.32; 95% CI: 1.08 to 1.60; p ¼ .008), and lower TLR (RR 0.41; 95%
CI 0.23 to 0.74; p¼ .002) and binary restenosis (RR 0.36; 95% CI 0.24 to 0.54; p < .0001) in diabetic patients after
12 months. Amputation and death rate did not differ signiﬁcantly. For DES versus BS, most trials showed equal
efﬁcacy between strategies.
Conclusion: Based on low- to moderate-quality evidence, PTA with optional bailout stenting using BS should
remain the preferred strategy in treating CLI patients with BTK arterial lesions. Before other strategies can be
implemented, larger and high-quality RCTs assessing clinically relevant outcomes are needed.
 2014 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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In 85% of patients with critical limb ischemia (CLI), arterial
lesions are located at the above-the-knee or below-the-knee
(BTK) arterial segments.1 In over 50%, the arterial stenosis or
occlusion is speciﬁcally located at the popliteal or tibial level.1
As a result of these arterial lesions, tissue perfusion is
decreased, clinically resulting into rest pain, or when an ulcerresponding author. S. Jens, Department of Radiology, Room G1-229,
ic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The
lands.
il address: s.jens@amc.uva.nl (S. Jens).
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//dx.doi.org/10.1016/j.ejvs.2014.02.012is present, impaired ulcer healing with possible secondary
infection and gangrene.2 The prognosis for patientswith CLI is
poor, as 1 year after initial presentation, 30% of patients will
have had an amputation and 25% will have died.2
The aim of treatment for CLI is to prevent amputation by
restoring ulcer healing potential, and to prevent death. To
enable ulcer healing, revascularization of the limb is
essential, either by endovascular or surgical intervention.
According to the 2007 Trans-Atlantic Inter-Society
Consensus II (TASC II) guideline,2 there is increasing evi-
dence to support BTK endovascular treatment in patients
with CLI and with medical co-morbidity. Infrapopliteal
balloon angioplasty (PTA) and stenting is not advised for
patients with intermittent claudication.2
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cular intervention have been evaluated, such as PTA versus
drug-eluting balloon (DEB) angioplasty with optional bailout
stenting, or PTA versus primary stenting using a bare stent
(BS) or drug-eluting stent (DES). The idea behind DEBs and
DESs is that by delivering drugs such as paclitaxel or siroli-
mus, neointima formation will be inhibited and the occur-
rence of restenosis reduced.3,4 Thereby, tissue perfusion
may be improved for a longer period, increasing the po-
tential for ulcer healing. However, conclusive evidence on
this is still lacking.
We performed a systematic review to determine overall 1
to 48 month outcomes of RCTs comparing different endo-
vascular treatment strategies in BTK arterial segments in
patients with CLI, to select the best endovascular treatment
strategy in these patients.
MATERIALS AND METHODS
This review was conducted according to the Preferred
Reporting Items for Systematic Review and Meta-Analysis
(PRISMA) guideline.5 The protocol for this review was not
published or registered in advance. This review was con-
ducted together with a review on above-the-knee endo-
vascular interventions. We refer to that paper for a detailed
description of the materials and methods.6
Eligibility criteria
Types of studies. RCTs.
Types of patients. Patients with CLI treated for BTK
arterial stenosis or occlusion.
Types of intervention. Studies comparing (1) BS versus
PTA, (2) DES versus PTA, (3) DEB versus PTA, or (4) DES
versus BS.
Types of outcome measures. Wound healing, quality of
life, change in Rutherford classiﬁcation, amputation,
death, target lesion revascularization (TLR), bypasses
performed, binary restenosis (patency), late lumen loss,
stenosis grade, and event-free survival (EFS) for follow-
up periods of at least 1 month.
Information sources
Electronic databases, Medline (PubMed) and OVID Embase,
were searched from 1980 to the present. The last search
was performed on 5 November 2013.
Search strategy
A detailed search strategy is provided in Appendix 1 (online
supplementary material).
Study selection
Two authors (SJ and AC) independently assessed eligibility
ﬁrst by screening titles and abstracts of the identiﬁed arti-
cles, after which both authors assessed full texts of the
remaining eligible articles.Methodological quality and risk of bias in individual
studies
For assessing methodological quality the Cochrane Collab-
oration’s tool for assessing risk of bias was used.7 Addi-
tionally, the presence of baseline differences between the
intervention and the comparator strategies for several risk
factors in peripheral arterial disease were scored.
Data extraction
Two authors (SJ and AC) independently extracted the data
from the included articles, after which consensus was
reached. For all outcomes extracted,when separate datawere
available for patients with CLI, these data were preferred.
Summary estimates of outcomes
Overview of summary estimates. Multiple outcomes were of
interest for this review. For dichotomous outcomes such as
wound healing, change in Rutherford classiﬁcation (when
dichotomized), amputation, and death, the risk ratio (RR) was
theprinciple summarymeasure. For continuousoutcomes, the
summary measure was the weighted mean difference (MD).
Pooling of summary estimates
Data were pooled using the random effects model. Het-
erogeneity was not tested statistically, but assumed a priori,
because of differences in population and lesion character-
istics and the use of different types of stents or balloons
between studies.
Quality of evidence
For every outcome the quality of evidence was assessed in
consensus by two authors (SJ and AC) according to the
Grading of Recommendations Assessment, Development
and Evaluation (GRADE) system.8 For this review, because of
the inability to assess inconsistency and publication bias for
most outcomes, quality of evidence was downgraded to
moderate quality in advance for all outcomes. Risk of bias
was deﬁned as present, when ﬁve or more items on the
Cochrane Collaboration’s tool were graded as unclear or
high risk of bias. Imprecision was deﬁned as present when
less than 100 patients were evaluated for an outcome.
Summary of ﬁndings per comparison
Finally, the quality of evidence and the results of each trial
were combined in one value to give an overview of the
ﬁndings. When outcomes between strategies were signiﬁ-
cantly different (p < .05) in favor of the intervention
strategy the outcomes were scored as þ, þþ, or þþþ,
depending on the corresponding quality of evidence. When
a signiﬁcant difference was in favor of the comparator
strategy, the outcomes were scored as -, - -, or - - -,
depending on the corresponding quality of evidence. When
outcomes between strategies were not signiﬁcantly
different (p  .05) the outcomes were scored as ¼, ¼ ¼,
or ¼ ¼ ¼, depending on the corresponding quality of evi-
dence. When conﬂicting evidence was present, and data
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depicted in the summary of ﬁndings table.RESULTS
Study selection
The search yielded 3658 articles, 2758 in Medline and 900
in Embase. Removal of 427 duplicates led to 3231 articles to
be assessed for eligibility based on title and abstract. This
resulted in exclusion of 3167 articles. For 64 articles, full-
text had to be assessed before deciding whether they
were eligible for this systematic review. Fifty-one articles
were excluded, as 29 were RCTs of above-the-knee inter-
vention, 21 were only abstracts for conference meetings,
and one was a protocol publication. Finally, 13 articles9e21
were included in this review. Fig. 1 is a ﬂow diagram of
the selection process.Study characteristics
Patients. The 13 included articles were publications of 12
RCTs of 1145 patients in total. In these trials, six (6 publi-
cations,9e14 379 patients) compared BS with PTA, two (2
publications,14,15 228 patients) DES with PTA, two (2 pub-
lications,16,17 182 patients) DEB with PTA, and four (5
publications,14,18e21 381 patients) DES with stent. Eight
trials included only patients with CLI, and, overall, for all
studies reporting prevalence of IC and CLI, patients had CLI
in 90% of patients. For all trials, the mean age ranged be-
tween 67 and 76 years, 65% of the patients were male, 67%
had diabetes, and 30% were smokers. The mean lesion
length for RCTs ranged between 11 and 130 mm (median
30 mm). Full study characteristics are shown in Table 1.
Comparisons. One trial14 compared four strategies
directly: PTA, PTA with intravenous (iv.) abciximab admin-
istration, BS with iv. abciximab administration and DES with
iv. abciximab administration. As the effect of abciximab was
not of interest for this review, the groups compared wereFigure 1. Flow diagram of search and study selection. RCT, ran-
domized controlled trial.the ones with abciximab administration. The two trials14,15
comparing DES with PTA, and three14,18e20 of the four tri-
als comparing DES with BS, used sirolimus-eluting stents.
The other trial21 comparing DES versus BS used an
everolimus-eluting stent. All trials on DEB used paclitaxel-
coated balloons.16,17 One16 of these trials studied DEB in
both above-the-knee and BTK arterial lesions.
Outcomes. Follow-up of patients varied from 1 to 48
months. The primary end point reported for most trials was
6-month or 1-year primary patency, binary restenosis, or
late lumen loss. One trial9 comparing BS with PTA, reported
1-year Rutherford classiﬁcation change, and one trial11 re-
ported 3- and 9-month clinical improvement, that is based
on the American Heart Association Clinical Improvement
Score, and limb salvage as primary end point.
Methodological quality and risk of bias
For all trials, allocation concealment and sequence gener-
ation were performed adequately or were not sufﬁciently
reported, resulting in an unclear risk of bias. One trial17 (8%)
had a low risk of bias for baseline characteristics, whereas
ﬁve trials9,11e14 (42%) had differences in baseline charac-
teristics, and were therefore subject to a high risk of bias.
Blinding during intervention was not possible for trials
comparing BS or DES with PTA, resulting in 11 trials9e17,20,21
(92%) with a high risk of bias. One trial18,19 was able to blind
the use of DES versus BS during intervention. For item
blinding during outcome assessment, incomplete outcome
data, and selective outcome reporting, the majority of trials
had a low or unclear risk of bias. Two trials16,17 (17%) had a
low risk for other biases, whereas the other trials (83%) had
a high risk of bias because of high loss to follow-up rate or
the ability for selective additional treatments.
Methodological quality per trial is shown in Fig. 2, and
overall methodological quality of trials per risk of bias item
is shown in Fig. 3.
Summary of ﬁndings per comparison
The summary of ﬁndings for each outcome is depicted in
Table 2. The outcomes extracted from every trial are shown
in Appendix 2 (online supplementary material). An overview
of the quality of evidence per outcome is shown in
Appendix 3 (online supplementary material). The summary
ﬁndings per comparison are described below.
BS versus PTA. Trials on wound healing, change in Ruth-
erford classiﬁcation, and amputation rate had mainly a low-
or very low-quality of evidence. Overall, most outcomes
were equal for the BS and PTA strategy between 1 and 48
months follow-up. Six-month restenosis showed conﬂicting
evidence for the BS strategy compared with PTA. A meta-
analysis of two trials13,14 showed signiﬁcantly less reste-
nosis in the PTA group (RR 1.69, 95% CI: 1.17 to 2.44,
p ¼ .005), whereas one trial10 performed KaplaneMeier
survival analysis, and reported that 79.7% of patients in the
BS group and 45.6% in the PTA group were free from binary
restenosis, with a statistically signiﬁcant difference
(p ¼ .0235). One other trial performing the same analysis
Table 1. Study and patient characteristics.
First
author
Comparison Patients,
N
% FII/FIII/
FIV or
IC/CLI
Lesions,
N
Age (y),
mean (SD)
or median
(range)
Males,
N (%)
Smoking,
N (%)
Diabetes,
N (%)
Renal
failure,
N (%)
CAD,
N (%)
Stroke,
N (%)
Hyperlipidemia,
N (%)
Hypertension,
N (%)
Occlusions,
N (%)
Stenosis
in %,
mean
(SD)
Lesion
length
(mm),
mean (SD)
Primary
outcome
Industry
sponsored
BS vs PTA
Brodmann
20119
Carbon-S 54 0/39/61 54 73 (2) 26 (48) 15 (28) 40 (74) d 47 (87) 47 (87) 20 (37) 46 (85) 16 (30) d d 1 y RF
improvement
No
Rand 200610 Carbon-S 51 0/24/76 95 Mean
72
(47e80)
d 31 (61) 35 (69) 8 (16) 20 (39) d 50 (98) d 7 (7) d 24 (5e30) 6 mo patency
rate
No
Rand 201111 Carbon-S 89 0/12/88 131 72 (9) 58 (65) d 69 (78) d d d d d 31 (24) 69 (21) d 3 and 9 mo
clinical
improvement
and limb
salvage
Yes
Randon 201012 Variety of S 38 0/13/87 56 72 (10) 20 (53) 5 (13) 22 (58) 10 (26) 30 (79) 5 (13) 16 (42) 38 (100) 36 (64) d d 1 y freedom
from
amputation
and primary
patency
No
Bosiers 200913 AMS 117 0/27/73 149 74 (8) 72 (62) 50 (43) 82 (70) d d d 67 (57) 102 (87) d d 11 (5) 30 d safety
(major amp/
death) and
6 mo patency
Yes
Tepe 201014 BMS
abciximab vs
POBA
abciximab
30 0/0/100 30 75 (d) 18 (60) 2 (7) 22 (73) d d d 13 (43) 21 (70) 10 (33) 89 (d) 33 (17) 6 mo primary
restenosis
Not
reported
DES vs PTA
Scheinert
201215
Sirol-ES 200 FIIeFIV 228 73 (9) 143 (72) 65 (33) 129 (65) d 90 (45) d 146 (73) 181 (91) 179 (79) d 27 (21) 12 mo binary
restenosis
Yes
Tepe 201014 Sirol-ES
abciximab vs
POBA
abciximab
28 0/0/100 28 71 (d) 16 (57) 4 (14) 21 (75) d d d 12 (43) 22 (79) 8 (29) 90 (d) 29 (21) 6 mo primary
restenosis
Not
reported
DEB vs PTA
Fanelli 201216 PTX-EB d FIIeFIV 30 d d d d d d d d d 12 (40) 86 (5) d 6 mo LLL No
Liistro 201317 PTX-EB 132
(143
limbs)
FIIIeFIV 158 75 (10) 106 (80) 20 (15) 132 (100) d 22 (17) 12 (9) 39 (30) 98 (74) 126 (80) 97 (8) 130 (81) 12 mo binary
restenosis
No
DES vs BS
Rastan 201119/
201218
Sirol-ES vs
BMS
161 53/47 161 73 (9) 107 (66) 46 (29) 87 (54) 57 (35) d d 123 (76) 145 (90) 36 (22) 88 (9) 31 (9) 1 y primary
patency rate
Yes
Falkowski
200920
Sirol-ES vs
BMS
50 68/20/12 50 mean 69
(53e58)
29 (58) 22 (44) 20 (40) d 21 (42) 7 (14) 18 (36) 31 (62) d d 18 (3) 6 mo restenosis Not
reported
Tepe 201014 Sirol-ES
abciximab vs
BMS
abciximab
30 0/0/100 30 73 (d) 16 (53) 2 (7) 15 (50) d d d 9 (30) 21 (70) 10 (33) 89 (d) 31 (21) 6 mo primary
restenosis
Not
reported
Bosiers 201221 Everol-ES vs
BMS
140 0/45/55 154 76 (8) 89 (64) 45 (32) 77 (55) 44 (31) d d 53 (38) 96 (69) 25 (14) d 17 (10) 1 y primary
patency
Yes
AMS ¼ absorbable metal stent; BMS ¼ bare metal stent; BS ¼ bare stent; CAD ¼ coronary artery disease; d ¼ days; DEB ¼ drug-eluting balloon; DES ¼ drug-eluting stent; EB ¼ eluting
balloon; ES ¼ eluting stent; Everol ¼ everolimus; FII/FIII/FIV ¼ Fontaine stage II, III, or IV; LLL ¼ late lumen loss; mo ¼ month; N ¼ number; PTA ¼ plain old balloon angioplasty;
PTX ¼ paclitaxel; RF ¼ Rutherford; S ¼ stent; SD ¼ standard deviation; Sirol ¼ sirolimus; y ¼ years.
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Figure 2. Methodological quality and risk of bias per individual RCT.
The items were scored as adequate (þ), unclear (?), or inadequate
(-). The ﬁgure is divided into four parts, from top to bottom,
respectively, BS versus PTA, DES versus PTA, DEB versus PTA, and
DES versus BS. * The study of Tepe et al. compared multiple stra-
tegies, that is BS versus PTA, DES versus PTA, and DES versus BS.
Figure 3. Methodological quality per item.
540 S. Jens et al.reported no statistically signiﬁcant difference on the 6-
month binary restenosis between groups. Fig. 4 shows a
meta-analyses and forest plots of 6-month TLR and binary
restenosis.
DES versus PTA. The quality of evidence was mainly very
low for the comparison DES versus PTA. Most outcomes,
that is wound healing, change in Rutherford classiﬁcation,
amputation, death, and TLR, were equal for the DES and
PTA strategy between 2 and 48 months follow-up. DES had
a beneﬁcial effect on binary restenosis and stenosis grade
compared with PTA at 12-month follow-up.
DEB versus PTA. For the comparison of DEB versus PTA,
12-month follow-up was available in diabetic patients. For
the outcomes wound healing (RR 1.28; 95% CI: 1.05 to 1.56;
p ¼ .01), change in Rutherford classiﬁcation (RR for Ruth-
erford improvement 1.32; 95% CI: 1.08 to 1.60; p ¼ .008),
TLR (RR 0.41; 95% CI: 0.23 to 0.74; p ¼ .002) and binary
restenosis (RR 0.36; 95% CI: 0.24 to 0.54; p < .0001),
moderate evidence in one trial17 showed a higher efﬁcacy
with the use of DEBs. The outcomes amputation and death
rate did not differ signiﬁcantly between strategies.
DES versus BS. Very low-quality evidence showed equal
wound healing rates between DES and BS. Some trials
showed a better efﬁcacy of DES for the outcome change in
Rutherford classiﬁcation, whereas other trials showed equal
efﬁcacy at 12-month follow-up. Most trials showed very
low- to moderate-quality evidence for equal efﬁcacy be-
tween strategies. For binary restenosis, late lumen loss, and
stenosis grade, low- to moderate-quality of evidence
showed a better efﬁcacy for the use of DES after 12-month
follow-up. Fig. 5 is a meta-analysis and forest plot of 12-
month binary restenosis.DISCUSSION
Summary of evidence
One trial17 comparing the use of paclitaxel-DEB with PTA,
showed moderate evidence of signiﬁcantly better wound
healing and Rutherford improvement, and lower TLR rate and
binary restenosis after 12-month follow-up with the DEB
strategy in diabetic patients. There is low to moderate evi-
dence showing that a primary stenting strategy using either
BS or sirolimus-DES does not perform better than PTA with
optional bailout strategy. Sirolimus- or everolimus-DES clini-
cally performed equally compared with BS, but performed
better in terms of binary restenosis and late lumen loss.Implications for practice
PTA with optional bailout stenting for BTK arterial lesions in
patients with CLI is still the preferred strategy. The use of
DEBs in these patients, especially diabetic patients, may be
beneﬁcial, but high-quality and adequately powered trials
focusing on clinical outcomes are needed before this
strategy can be implemented into standard clinical care. The
use of BS when bailout stenting is indicated is recom-
mended, as DES trials did not show clinical beneﬁt from DES
over BS.
Table 2. Summary of ﬁndings per comparison.
BS vs PTA 1 mo 2 mo 3 mo 6 mo 9 mo 12 mo 24 mo 24e48 mo
Wound healing ¼ ¼ e ¼
Quality of life
RF change ¼ ¼ ¼ ¼
Minor amputation ¼ ¼ ¼ ¼ ¼ ¼ ¼
Major amputation ¼ ¼ ¼ ¼ ¼ ¼ ¼ ¼ ¼ ¼ ¼ ¼ ¼ ¼
Total amputation ¼ ¼ ¼ ¼ ¼ ¼ ¼
Death ¼ ¼ ¼ ¼ ¼ ¼ ¼ ¼ ¼ ¼ ¼ ¼ ¼
TLR ¼ ¼ ¼ ¼ (MA) ¼
Bypass ¼ ¼ ¼
Binary restenosis ¼ - - (MA)/þ/¼ ¼ ¼ ¼ ¼ ¼
Late lumen loss e
Stenosis grade ¼
EFS
DES vs PTA 1 mo 2 mo 3 mo 6 mo 9 mo 12 mo 24 mo 24e48 mo
Wound healing - ¼ ¼
Quality of life
RF change ¼ ¼ ¼ ¼
Minor amputation ¼ ¼ ¼
Major amputation ¼ ¼ ¼
Total amputation ¼ ¼ ¼ ¼ ¼
Death ¼ ¼ ¼
TLR ¼ ¼ ¼
Bypass
Binary restenosis þ ¼ þþ
Late lumen loss ¼ ¼
Stenosis grade þþ
EFS
DEB vs PTA 1 mo 2 mo 3 mo 6 mo 9 mo 12 mo 24 mo 24e48 mo
Wound healing þþþ
Quality of life
RF change þþþ
Minor amputation ¼ ¼ ¼
Major amputation ¼ ¼ ¼
Total amputation ¼ ¼ ¼
Death ¼ ¼ ¼
TLR þþþ
Bypass
Binary restenosis þþþ
Late lumen loss þþ
Stenosis grade
EFS
DES vs BS 1 mo 2 mo 3 mo 6 mo 9 mo 12 mo 24 mo 24e48 mo
Wound healing ¼ ¼ ¼
Quality of life
RF change ¼ ¼ ¼ ¼ ¼ þþ
Minor amputation ¼ ¼ ¼ ¼ ¼ ¼
Major amputation ¼ ¼ ¼ ¼ ¼ ¼
Total amputation ¼ ¼ ¼ ¼ ¼ ¼
Death ¼ ¼ ¼ ¼ ¼ ¼ ¼ ¼
TLR ¼ þ þþþ/¼ ¼
Bypass
Binary restenosis ¼ þþ (MA) þþþ (MA)
Late lumen loss þ þþ
Stenosis grade þþ
EFS ¼ ¼
þ, þþ, or þþþ refers to, respectively, very low-, low-, or moderate-quality evidence for a signiﬁcant difference (p < .05) in favor of the
intervention strategy. -, - -, or - - - refers to, respectively, very low-, low-, or moderate-quality evidence for a signiﬁcant difference (p < .05)
in favor of the comparator strategy (e.g. PTA). ¼, ¼ ¼, or ¼ ¼ ¼ refers to, respectively, very low-, low-, or moderate-quality evidence for
non-signiﬁcant difference (p  .05) between strategies. When conﬂicting evidence was present in trials, and data could not be pooled,
both qualities of evidence were depicted.BS ¼ bare stent; DEB ¼ drug-eluting balloon; DES ¼ drug-eluting stent; mo ¼ month;
EFS ¼ event-free survival; MA ¼ meta-analysis; PTA ¼ plain old balloon angioplasty; RF ¼ Rutherford; TLR ¼ target lesion revascularization.
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BS versus PTA
6 mo binary restenosis
6 mo TLR
BS PTA
Favours BS Favours PTA
BS PTA
Favours BS Favours PTA
Bosiers 2009
Tepe
Bosiers 2009
Tepe
p
p
p
p
to
to
to
to
to
to
Figure 4. Forest plots of 6-month target lesion revascularization (TLR) and binary restenosis of bare stent (BS) versus plain old balloon
angioplasty (PTA).
542 S. Jens et al.Limitations of this study
Clinically relevant end points for patients with CLI are
wound healing, quality of life, and limb salvage. However,
most outcomes reported by the trials included in our review
were radiological, such as primary patency, binary reste-
nosis, and late lumen loss. Moreover, only three trials re-
ported on wound healing and not a single trial assessed
change in quality of life or functional status using a disease-
speciﬁc questionnaire. More trials assessing patient re-
ported outcomes are needed before the most clinically
relevant endovascular strategy can be selected conﬁdently.
In the meta-analysis we pooled the results of trials with
different types of stents, such as balloon- or self-expandable
stents, and different drugs for drug-eluting stents, that is
sirolimus- and everolimus-eluting stents. Everolimus is a
derivative of sirolimus, and a recent RCT on coronary artery
stenting showed no signiﬁcant differences in clinical and
angiographic outcomes.22 However, combining outcomes of
different types of stents results in an overall outcome, and
cannot identify which type of stent performs best.
The majority of patients with CLI will have multilevel dis-
ease.1 For adequate treatment of such patients, hemody-
namic inﬂow, that is proximal lesions, should be restored
before BTK lesions are treated. Several trials reported that, at
the judgment of the interventional radiologist, proximal le-
sions could be treated ﬁrst. It remains, therefore,DES versus
12 mo binary restenosis
DES BS
Rastan
Bosiers 2012
p
p
Figure 5. Forest plots of 12-month binary restenosis oquestionable whether this could have introduced a selection
or performance bias, by for instance treating proximal lesions
in patients elected for BTK stenting more extensively.
Four out of twelve trials included patients with inter-
mittent claudication, and in two of these trials such patients
were in the majority.18e20 For patients with intermittent
claudication, the clinical outcomes such as wound healing,
amputation, and death are not relevant or the event rate is
very low. Therefore, by including these patients, the com-
parison between strategies is more likely to give equal re-
sults. This is a major weakness of these trials, and leads to
underestimations of potentially signiﬁcant differences be-
tween strategies, and therefore results are not directly
applicable to the majority of practice.
The quality of evidence assessment by the GRADE system
could not be performed for all domains. The domains het-
erogeneity and publication bias could not be assessed for
one outcome, as the outcomes and follow-up times be-
tween studies varied. To compensate for this, quality of
evidence was downgraded at forehand with one grade.
Therefore, no outcome could have the highest quality of
evidence. Moreover, because of the poor scores of many
studies on the risk of bias assessment, quality of evidence
was low for several outcomes. This low quality of evidence
severely affects the strength of recommendation given in
this review. BS
Favours DES Favours BS
to
to
to
f drug-eluting stent (DES) versus bare stent (BS).
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the standard operating procedure.2 However, several trials
considered bailout stenting as a failure for the PTA strategy,
resulting in irrelevant data reported for the outcomes bi-
nary restenosis and TLR. These data were excluded from this
review as bailout stenting is incorporated in the PTA
strategy.
Considering the abovementioned limitations, future
studies should improve their methodological quality.
Furthermore, when comparing two stents, future trials
need to shift their focus to comparing bailout DES with
bailout BS. Several trials are being performed currently,
such as the EXPAND,23 SENS-BTK24 (both nitinol stent versus
PTA), INPACT-DEEP,25 Lutonix-BTK26 (both DEB versus PTA),
and the PADI trial27 (DES versus PTA). Four of these trials
still have an angiographic outcome as primary outcome, but
sample sizes are larger, ranging between 94 and 480 pa-
tients. Three of these trials are industry sponsored, and four
trials include only CLI patients. Unpublished results of the
INPACT-DEEP trial recently resulted in a safety warning and
a recall for all INPACT Amphirion DEBs.25 The trial showed a
trend towards a higher 12-month major amputation rate in
the DEB group, without a speciﬁc causal relationship after
subgroup and multivariate analysis.
We did not ﬁnd any cost-effectiveness analyses. Yet,
these are important as strategies other than PTA, especially
using drug-eluting devices, are expensive.28 For imple-
menting new strategies, evidence for cost-effectiveness of
the new strategy must be available.
CONCLUSION
The generally low- to moderate-quality of evidence makes it
difﬁcult to draw ﬁrm conclusions. Nevertheless, the avail-
able evidence indicates that PTA with optional bailout
stenting should remain the preferred strategy in treating CLI
patients with BTK arterial lesions. Before other strategies
can be implemented, larger and high-quality RCTs assessing
clinically relevant outcomes are needed.
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